The future of cancer precision therapy is here
We measures circulating cancer cells as they travel toward metastatic spread, while we develop therapy to attack these metastasizing cancer cells.
THE STRATEGIC ANCHOR
“Know the enemy and know yourself; in a hundred battles you will never be defeated”
— Sun Tzu (544 - 596 BC) - The Art of War
Tzu is pioneering the development of precision therapies attacking metastatic cancer, the leading cause of cancer death.
Our cancer therapies are based on in-depth knowledge of circulating tumor cells (CTCs), which cause metastasis and are the real enemy.
TECHNOLOGY
TzuPlus
We established TzuPlus technology to get the deepest understanding of metastasizing cancer cells. TzuPlus maps 3 layers (DNA, mRNA, and surface proteins) for each individual circulating tumor cell.
Our clinically validated approach allows the screening of large blood volumes. A growing database of circulating tumor cell molecular information provides a gateway towards effective cancer precision therapy against metastatic disease.
™
01
Surface proteins
Multiplex surface protein expression analysis
200x
More circulating tumor cells recovered vs. conventional methods, from clinically validated large-volume blood screening.
02
03
mRNA
Full-length mRNA sequencing of single CTCs
DNA
Genome-wide mutational profiling of single CTCs
01
Improving early drug
evaluation
Tzu measures target expression and resistance mechanisms in clinical evaluation.
02
Target identification and validation in pre-treated metastatic disease
Tzu provides target expression data in pre-treated, actively metastasizing disease.
03
Patient stratification
Tzu CTC target expression analysis can identify target expression correlation with overall response rates.
FOR PHARMA
Accelerating translation
Tzu offers clinical evaluation information for pharma partners.
dr. Wigard Kloosterman
CEO
dr. Ronald Plasterk
Founder & CSO
dr. Michiel Stevens
CTO
Noëlle Beute
COO
dr. Mike Shaw
CBO
dr. Debora Meijer
Bioinformatician
dr. Alberto Gil Jimenez
Bioinformatician
dr. Joost Swennenhuis
Senior Scientist
Andre Verwei
CFO
Sara Astarita
Medical Associate
TEAM
Meet the team
Great science starts with great people. We are scientists, engineers, and thinkers who show up with curiosity, rigour, and a common purpose.
FOR INVESTORS
An investment thesis grounded in technology
Metastasis causes the majority of cancer deaths, and remains largely unaddressed by today’s therapies. Tzu turns the biology of circulating tumor cells into a proprietary data and discovery engine for the next generation of precision oncology.
NEWS
Recent updates
-
![]()
Convention | BIO San Diego
-
![]()
Congress | EACR Budapest
-
![]()
Appointment | Mike Shaw as CBO
-
![]()
Round Table | HI-NL
-
![]()
Update | Processing our first blood samples
-
![]()
Seminar | Brigitte and Dr. Konstanze Wegener Seminar
-
![]()
Update | Our new FACS device
-
![]()
Interview | Sara Astarita
-
![]()
Update | Solve with Google Hackathon
-
![]()
Conference | ESMO
-
![]()
Interview | Joost Swennenhuis
-
![]()
Press release | Acquisition of Fetch B.V.
-
![]()
Interview | Alberto Gil Jimenez
-
![]()
Interview | Debora Meijer
-
![]()
Interview | Jenneke Wijling
